16.7m Performance Rights will vest once Xref achieves annualised EBITDA of A$5m within 5 years from Listing 15.2 million options, with 0.9 million at $0.585 exercise price, 0.5 million at $0.66exercise price, and 13.8 million at $0.70 exercise price, which expire between February 2021 and September 2023